In recent trading session, Actuate Therapeutics Inc (NASDAQ:ACTU) saw 0.52 million shares changing hands at last check today with its beta currently measuring 0. Company’s recent per share price level of $6.22 trading at -$0.01 or -0.08% at last check today assigns it a market valuation of $122.13M. That most recent trading price of ACTU’s stock is at a discount of -92.77% from its 52-week high price of $11.99 and is indicating a premium of 11.58% from its 52-week low price of $5.50. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.11 million shares which gives us an average trading volume of 96.06K if we extend that period to 3-months.
Actuate Therapeutics Inc (NASDAQ:ACTU) trade information
Upright in the red during last session for losing -0.08%, in the last five days ACTU remained trading in the green while hitting it’s week-highest on Thursday, 07/17/25 when the stock touched $6.22 price level, adding 14.44% to its value on the day. Actuate Therapeutics Inc (NASDAQ:ACTU) showed a performance of -25.63% in past 30-days. Number of shares sold short was 0.24 million shares which calculate 3.74 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 21 to the stock, which implies a rise of 70.38% to its recent value today. Analysts have been projecting 21 as a low price target for the stock while placing it at a high target of 21. It follows that stock’s current price would drop -237.62% in reaching the projected high whereas dropping to the targeted low would mean a loss of -237.62% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 66.26% while estimates for its earnings growth in next 5 years are of 12.89%.
Actuate Therapeutics Inc (NASDAQ:ACTU)’s Major holders
Insiders are in possession of 18.94% of company’s total shares while institution are holding 53.53 percent of that, with stock having share float percentage of 66.04%. Investors also watch the number of corporate investors in a company very closely, which is 53.53% institutions for Actuate Therapeutics Inc that are currently holding shares of the company.
On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Northern Funds-SMALL CAP CORE FUND are the top two Mutual Funds which own company’s shares. As of May 31, 2025 , the former fund manager was holding 16.71 shares of worth $0.1 million or 0.09% of the total outstanding shares. The later fund manager was in possession of 15.8 shares on Mar 31, 2025 , making its stake of worth around $96531.0 in the company or a holder of 0.08% of company’s stock.